Regeneron Pharmaceuticals (REGN) Exchange Rate Effect (2023 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Exchange Rate Effect of -$300000.0 for Q2 2026, down 175.0% year-over-year from $400000.0 in Q2 2025, and up 66.67% quarter-over-quarter from -$900000.0 in Q1 2026.
Regeneron Pharmaceuticals (REGN) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Exchange Rate Effect history runs 4 years deep, the most recent figure standing at -$300000.0 for Q2 2026.
- In Q2 2026, Exchange Rate Effect fell 175.0% year-over-year to -$300000.0; the TTM figure through Jun 2026 stood at -$1.9 million (down 272.73% YoY), while the FY2025 annual figure was $300000.0, up 142.86% from the prior year.
- Exchange Rate Effect for Q2 2026 stood at -$300000.0, up from -$900000.0 in the prior quarter.
- The five-year high for Exchange Rate Effect was $800000.0 in Q3 2024, with the low at -$900000.0 in Q1 2026.
- The 4-year median for Exchange Rate Effect is -$300000.0 (2024), against an average of -$153846.2.
- Peak annual rise in Exchange Rate Effect reached 500.0% in 2024, while the deepest fall reached 450.0% in 2024.
- Regeneron Pharmaceuticals' Exchange Rate Effect stood at $200000.0 in 2023, then slumped by 450.0% to -$700000.0 in 2024, then jumped by 57.14% to -$300000.0 in 2025, then changed by 0.0% to -$300000.0 in 2026.
- Business Quant data shows REGN's Exchange Rate Effect at -$300000.0 in Q2 2026, -$900000.0 in Q1 2026, and -$300000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 315,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -300,000.00 |
| Jun 30, 2026 | -300,000.00 |
| Mar 31, 2026 | -900,000.00 |
| Mar 31, 2026 | -900,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Dec 31, 2025 | -300,000.00 |
| Sep 30, 2025 | -400,000.00 |
| Sep 30, 2025 | -400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 400,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | -700,000.00 |
| Dec 31, 2024 | -700,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | -300,000.00 |
| Jun 30, 2024 | -300,000.00 |
| Mar 31, 2024 | -500,000.00 |
| Mar 31, 2024 | -500,000.00 |